Yarrow Bioscience (YARW) Liabilities and Shareholders Equity (2016 - 2026)

Yarrow Bioscience (YARW) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $25.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 54.14% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.2 million (down 45.08% YoY) and the FY2025 annual result came in at $30.2 million, down 54.92% from the prior year.
• Liabilities and Shareholders Equity fell to $25.9 million in Q1 2026, from $30.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $97.7 million in Q4 2023 to a low of $19.3 million in Q3 2023.
• A 5-year average of $53.9 million and a median of $51.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 58.93% — and 2024, when it surged 295.48%.
• Tracing YARW's Liabilities and Shareholders Equity over 5 years: stood at $40.8 million in 2022, then surged by 139.67% to $97.7 million in 2023, then sank by 31.51% to $66.9 million in 2024, then slumped by 54.92% to $30.2 million in 2025, then retreated by 14.21% to $25.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $25.9 million (Q1 2026), $30.2 million (Q4 2025), and $44.7 million (Q2 2025), per Business Quant data.